Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient.

Rosa María García-Álvarez Maruxa Zapata-Cachafeiro Irene Visos-Varela Almudena Rodríguez-Fernández Samuel Pintos-Rodríguez María Piñeiro-Lamas María Teresa Herdeiro Adolfo Figueiras Ángel Salgado-Barreiranull null

Published in: Inflammopharmacology (2024)

This large-scale real-world data study suggest that enalapril and candesartan are associated with a considerable reduction in risk of severe COVID19 outcomes.

Keyphrases

coronavirus disease
sars cov
electronic health record
respiratory syndrome coronavirus
adipose tissue
metabolic syndrome
deep learning